Nocturia - Epidemiology Forecast to 2028
Markets Covered
United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2016-2028
Nocturia Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Nocturia in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders views are also taken into account to provide a deep understanding of the Nocturia outlook. It also includes the explanation of changing trends of epidemiology outlining the Nocturia scenario.
Nocturia Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Nocturia thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.
Report Scope
The report covers detailed overview of Nocturia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Nocturia Report assesses the disease risk and burden and highlights the unmet needs
It also helps to recognize the growth opportunities in the 7MM with respect to the patient population
Key strengths
10 Year Forecast
7MM Coverage
Total Cases in Nocturia
Key assessments
Patient Segmentation in Nocturia
Nocturia Risk & Burden
Factors driving growth in a specific Nocturia patient population
2. Nocturia Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Nocturia in 2016
2.2. Patient Share Distribution of Nocturia in 2028
3. Disease Background and Overview: Nocturia
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Nocturia in 7MM
4.3. Total Prevalent/ Incident Patient Population of Nocturia in 7MM By Countries
5. Epidemiology of Nocturia by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Nocturia
5.1.3. Sub-Type Specific cases of the Nocturia *
5.1.4. Sex- Specific Cases of the Nocturia *
5.1.5. Diagnosed Cases of the Nocturia
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Nocturia
5.4.3. Sub-Type Specific cases of the Nocturia *
5.4.4. Sex- Specific Cases of the Nocturia *
5.4.5. Diagnosed Cases of the Nocturia
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Nocturia
5.5.3. Sub-Type Specific cases of the Nocturia *
5.5.4. Sex- Specific Cases of the Nocturia *
5.5.5. Diagnosed Cases of the Nocturia
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Nocturia
5.6.3. Sub-Type Specific cases of the Nocturia *
5.6.4. Sex- Specific Cases of the Nocturia *
5.6.5. Diagnosed Cases of the Nocturia
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Nocturia
5.7.3. Sub-Type Specific cases of the Nocturia *
5.7.4. Sex- Specific Cases of the Nocturia *
5.7.5. Diagnosed Cases of the Nocturia
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Nocturia
5.8.3. Sub-Type Specific cases of the Nocturia *
5.8.4. Sex- Specific Cases of the Nocturia *
5.8.5. Diagnosed Cases of the Nocturia
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Nocturia
5.9.3. Sub-Type Specific cases of the Nocturia *
5.9.4. Sex- Specific Cases of the Nocturia *
5.9.5. Diagnosed Cases of the Nocturia
6. Unmet Needs of the Nocturia
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
List Of Tables
Table 1: Total Prevalent/Incident Cases of the Nocturia in 7MMTable 2: Total Prevalent/Incident Cases of the Nocturia in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Nocturia in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Nocturia in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Nocturia in United States (2016-2028)*
Table 6: Diagnosed Cases of the Nocturia in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Nocturia in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Nocturia in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Nocturia in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Nocturia in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Nocturia in France (2016-2028)
Table 12: Sub-Type Specific cases of the Nocturia in France (2016-2028) *
Table 13: Sex- Specific Cases of the Nocturia in France (2016-2028) *
Table 14: Diagnosed Cases of the Nocturia in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Nocturia in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Nocturia in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Nocturia in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Nocturia in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Nocturia in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Nocturia in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Nocturia in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Nocturia in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Nocturia in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Nocturia in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Nocturia in UK (2016-2028) *
Table 26: Diagnosed Cases of the Nocturia in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Nocturia in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Nocturia in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Nocturia in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Nocturia in Japan (2016-2028)
List Of Figures
Figure 1: Total Prevalent/Incident Cases of the Nocturia in 7MMFigure 2: Total Prevalent/Incident Cases of the Nocturia in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Nocturia in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Nocturia in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Nocturia in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Nocturia in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Nocturia in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Nocturia in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Nocturia in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Nocturia in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Nocturia in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Nocturia in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Nocturia in France (2016-2028) *
Figure 14: Diagnosed Cases of the Nocturia in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Nocturia in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Nocturia in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Nocturia in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Nocturia in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Nocturia in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Nocturia in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Nocturia in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Nocturia in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Nocturia in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Nocturia in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Nocturia in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Nocturia in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Nocturia in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Nocturia in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Nocturia in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Nocturia in Japan (2016-2028)
Nocturia Disease - Global Clinical Trials Review, H2, 2020
Nocturia Disease - Global Clinical Trials Review, H2, 2020Thes clinical trial report, Nocturia Disease - Global Clinical Trials Review, H2, 2020 provides an overview of Nocturia Clinical trials scenario. This
USD 2500 View ReportNocturia - Pipeline Review, H2 2019
Nocturia - Pipeline Review, H2 2019Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H2 2019, provides an overview of the Nocturia (Genito Urinary System
USD 2000 View ReportPlaque Psoriasis - Epidemiology Forecast to 2030
Plaque Psoriasis - Epidemiology Forecast to 2030Plaque psoriasis is a common and incurable chronic immune-mediated skin disease characterized by red and flaky patches that are itchy and can be painful
USD 3995 View ReportSystemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030
Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030Systemic sclerosis (SSc) is an autoimmune disorder of small arteries, microvessels, and connective tissue. SSc is characterized by the buildup of scar tissue
USD 3995 View ReportFill The Form For Sample Request